Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2008-07-22
2008-07-22
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S556000
Reexamination Certificate
active
10069574
ABSTRACT:
The invention concerns the use of monohydroxy or polyhydroxy amino acids, and the lactone forms thereof for making medicines with insulin-analogue and/or insulin-sensitizing effects on peripheral tissues targeted by insulin, and more particularly the use thereof for making medicines for treating and preventing insulin-resistance.
REFERENCES:
patent: 4529589 (1985-07-01), Davydov et al.
patent: 5178867 (1993-01-01), Guittard et al.
patent: 5470879 (1995-11-01), Sauvaire et al.
patent: 5591709 (1997-01-01), Lindenbaum
patent: 5847109 (1998-12-01), Garti et al.
patent: 5997877 (1999-12-01), Chang
patent: 2695317 (1994-03-01), None
patent: 2745718 (1997-09-01), None
patent: 9618313 (1996-06-01), None
patent: 9821592 (1998-05-01), None
patent: 9832017 (1998-07-01), None
Windholz et al., The Merck Index, Tenth Edition (1983), pp. 723-724, abstract No. 4866.
Yves Sauvaire et al., “4-hydroxyisoleucine: A Novel Amino Acid Potentiator of Insulin Secretion”, Diabetes, (Feb. 1998) 47(2), pp. 206-210.
Broca, C. et al;“Intracellular Signalling and 4-Hydroxyisoleucine Insulinotropic Effect”; Diabetologia; Aug. 1999, vol. 42, No. Suppl. 1, p. A129, XP000910386.
Broca, C. et al.; “4-Hydroxyisoleucine: Experimental Evidenced of its Insulinotropic and Antidiabetic Properties”; American Journal of Physiology; Oct. 1999, vol. 277, No. 4 Part 1, p. E617-E623; XP000908984.
Broca, C. et al; “4-Hydroxyisoleucine Improves Glucose Tolerance in Normal and NIDDIM Animals”; Biabetologia, Aug. 1998, vol. 41, No. Suppl. 1, p. A239, XP00090899.
Ricort JM et al; “Alterations in Insulin Signalling Pathway Induced by Prolonged Insulin Treatment of 3T3-L1 Adipocytes”; Diabetologia, Oct. 1995, 38, 1148-56, XP000909007.
Withers DJ et al;. “Disruption of IRS-2 Causes Type 2 Diabetes in Mice”; Nature, GB, Macmillan Journals Ltd., London, vol. 391, No. 6670, Feb. 26, 1998, pp. 900-904, XP002119312.
Publication , G.Slama; “Doibetes: Classification Et Generalities”; pp. 1453-1458.
Search Report from European Patent Application No. EP 03 29 1523, Mar. 17, 2004.
Alcock et al., “Stereochemistry of 4-Hydroxyisoleucine From Trigonella Foenum-Graecum,” Phytochemistry 28:1835-1841, 1989.
Bordia et al., “Effect of Ginger (Zingiber Officinale Rosc.) and Fenugreek (Trigonella Foenumgraeum L.) on Blood Lipids, Blood Sugar and Platelet Aggregation in Patients with Coronary Artery Disease,” Prostaglandins, Leukotrienes and Essential Fatty Acids 56:379-387, 1997.
Broca et al., “4-Hydroxyisoleucine: Effects of Synthetic and Natural Analogues on Insulin Secretion,” Eur. J. Pharmacol. 390:339-345, 2000.
Fowden et al., “4-Hydroxyisoleucine from Seed of Trigonella Foenum-Graecum,” Phytochemistry 12:1707-1711, 1973.
Khosla et al., “Effect of Trigonella Foenum-Graecum (Fenugreek) on Blood Glucose in Normal and Diabetic Rats,” Indian J. Physiol. Pharmacol. 39:173-174, 1995.
Madar et al., “Glucose Lowering Effect of Fenugreek in Non-insulin Dependent Diabetics,” Eur. J. Clinical Nutrition 42:51-54, 1988.
Neeraja et al., “Hypoglycemic Effect of Processed Fenugreek Seeds in Humans,” J. Food Sci. Technol. 33:427-430, 1996.
Ohnuma et al., “Anaphylaxis to Curry Powder,” Allergy 53:452-454, 1998.
Patil et al., “Allergy to Fenugreek (Trigonella Foenum Graecum),” Ann. Allergy Asthma Immunol. 78:297-300, 1997.
Petit et al., “Steroid Saponins from Fenugreek Seeds: Extraction, Purification and Pharmacological Investigation on Feeding Behavior and Plasma Cholesterol,” Steroids 60:674-680, 1995.
Petit et al., “Effects of a Fenugreek Seed Extract on Feeding Behavior in the Rat; Metabolic-Endocrine Correlates,” Pharmacol. Biochem. Behav. 45:369-374, 1993.
Prasanna, “Hypolipidemic Effect Fenugreek: a Clinical Study,” Indian J. Pharmacol. 32:34-36, 2000.
Ribes et al., “Antidiabetic Effects of Subfractions from Fenugreek Seeds in Diabetic Dogs,” Proc. Soc. Exp. Biol. Med. 182:159-166, 1986.
Ribes et al., “Effect of Fenugreek Seeds on Endocrine Pancreatic Secretions in Dogs,” Ann. Nutr. Metab. 28:37-43, 1984.
Ribes et al., “Hypocholesterolaemic and Hypotriglyceridaemic Effects of Subfractions from Fenugreek Seeds in Alloxan Diabetic Dogs,” Phytotherapy Res. 1:38-43, 1987.
Sauvaire et al., “Implication of Steroid Saponins and Sapogenins in the Hypocholesterolemic Effect of Fenugreek,” Lipids 26:191-197, 1991.
Sauvaire et al, “Changes in Growth, Proteins and Free Amino Acids of Developing Seed and Pod of Fenugreek,” Phytochem. 23:479-486, 1984.
Sauvaire et al., “Chemistry and Pharmacology of Fenugreek,”Herbs, Botanicals&TeasEds. G. Mazza and B.D. Oomah, 107-129, 2000.
Sharma, “Effect of Fenugreek Seeds and Leaves on Blood Glucose and Serum Insulin Responses in Human Subjects,” Nutritions Res. 6:1353-1364, 1986.
Sharma et al., “Hypoglycaemic Effect of Fenugreek Seeds in Non-Insulin Dependent Diabetic Subjects,” Nutrition Res. 10:731-739, 1990.
Sharma et al., “Use of Fenugreek Seed Powder in the Management of Non-Insulin Dependent Diabetes Mellitus,” Nutr. Res. 16:1331-1339, 1996.
Sharma et al., “Effect of Fenugreek Seeds on Blood Glucose and Serum Lipids in Type I Diabetes,” Eur. J. Clin. Nutr. 44:301-306, 1990.
Sowmya et al., “Hypocholesterolemic Effect of Germinated Fenugreek Seeds in Human Subjects,” Plant Foods Hum. Nutr. 53:359-365, 1999.
Valette et al., “Hypocholesterolaemic Effect of Fenugreek Seeds in Dogs,” Atherosclerosis 50:105-111, 1984.
Al-Habori et al, “Antidiabetic and Hypocholesterolaemic Effects of Fenugreek,” Phytother. Res. 12:233-242, 1998.
Broca et al., “4-Hydroxyisoleucine: Experimental Evidence of its Insulinotropic and Antidiabetic Properties,” Am. J. Physiol. 277:E617-E623, 1999.
Sauvaire et al., “4-Hydroxyisoleucine A Novel Amino Acid Potentiator of Insulin Secretion,” Diabetes 47:206-210, 1998.
Alzaid, “Insulin Resistance in Non-Insulin-Dependent Diabetes Mellitus,” Acta Diabetol. 33:87-99, 1996.
Amer et al., “Different Aetiologies of Type 2 (Non-Insulin-Dependent) Diabetes Mellitus in Obese and Non-Obese Subjects,” Diabetologia 34:483-487, 1991.
Banerji et al., “Does Intra-Abdominal Adipose Tissue in Black Men Determine Whether NIDDM is Insulin-Resistant or Insulin-Sensitive?” Diabetes 44:141-146, 1995.
Bonora et al., “In Vivo Glucose Metabolism in Obese and Type II Diabetic Subjects With or Without Hypertension,” 42:764-772, 1993.
Byrne et al., “Elevated Plasma Glucose 2 h Postchallenge Predicts Defects in β-Cell Function,” Am. J. Physiol. 270:E572-E579, 1996.
Campbell et al., “Quantification of the Relative Impairment in Actions of Insulin on Hepatic Glucose Production and Peripheral Glucose Uptake in Non-Insulin-Dependent Diabetes Mellitus,” Metabolism 37:15-21, 1988.
Gerich, “Insulin Resistance is Not Necessarily an Essential Component of Type 2 Diabetes,” J. Clin. Endocrinol. Metab. 85:2113-2115, 2000.
Gerich, “The Genetic Basis of Type 2 Diabetes Mellitus: Impaired Insulin Secretion Versus Impaired Insulin Sensitivity,” Endocrine Rev. 19:491-503, 1998.
Groop et al., “Insulin Resistance, Hypertension and Microalbuminuria in Patients with Type 2 (Non-Insulin-Dependent) Diabetes Mellitus,” Diabetologia 36:642-647, 1993.
Groop et al., “Insulin Resistance and Insulin Deficiency in the Pathogenesis of Type 2 (Non-Insulin-Dependent) Diabetes Mellitus: Errors of Metabolism or of Methods?” Diabetologia 36:1326-1331, 1993.
Haffner et al., “Insulin Sensitivity and Acute Insulin Response in African-Americans, Non-Hispanic Whites, and Hispanics with NIDDM,” Diabetes 46:63-69, 1997.
Kalant et al., “Insulin R
Broca Christophe
Petit Roger Pierre
Ribes Gerard
Sauvaire Yves
Taouis Mohammed
Clark & Elbing LLP
Innodia Inc.
Kwon Brian-Yong S
LandOfFree
Use of amino acids for making medicines for treating to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of amino acids for making medicines for treating to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of amino acids for making medicines for treating to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3918259